Ayala Pharmaceuticals Inc (ADXS)

[runcaly]

New applications ( section 2.1 to 2.12 that include 2.7 New applications, 2.7.1. Axalimogene filolisbac - EMEA/H/C/004473 )
is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion (Day 205).

Agenda meeting 18.-20. April 2018 include Timetable for assessment
Action: for adoption ( or to adopt a draft opinion )

Once adopted, the CAT opinion is transmitted to the CHMP for final adoption ( Day 210 )

The CHMP opinion will be forwarded to the European Commission for a final decision valid throughout the EU ( Day 277 )

So if we are at Day 205 we have max. 72 Days until approval (nearly beginning of July)